SCHEMBL3916038

SCHEMBL3916038

COC(OC)c1ccc(CO)cn1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 5/20 0.41
ESR2 Q92731 5/20 0.41
POLB P06746 2/20 0.37
RAB9A P51151 2/20 0.37
NPC1 O15118 1/20 0.37
L3MBTL1 Q9Y468 2/20 0.34
ALDH1A1 P00352 1/20 0.34
MAPT P10636 1/20 0.34
MAPK1 P28482 1/20 0.34
FYN P06241 1/20 0.33
CACNA1I Q9P0X4 1/20 0.32
HRH3 Q9Y5N1 1/20 0.32
EGLN2 Q96KS0 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.31
S1PR1 P21453 1/20 0.31
S1PR3 Q99500 1/20 0.31
PDE1B Q01064 1/20 0.31
HSD17B10 Q99714 1/20 0.31
CBFB Q13951 1/20 0.31
KMT2A Q03164 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31541690 0.84 ESR1 (0.40) ESR1ESR2POLBRAB9ANPC1
SCHEMBL6224406 0.81 ESR1 (0.38) ESR1ESR2POLBL3MBTL1ALDH1A1
SCHEMBL3913709 0.81 ESR1 (0.38) ESR1ESR2POLBL3MBTL1ALDH1A1
SCHEMBL22828115 0.80 SMN1; SMN2 (0.39) ESR1ESR2RAB9ANPC1L3MBTL1
Hydrochloric Acid SCHEMBL11011881 0.80 ESR1 (0.37) ESR1ESR2POLBL3MBTL1ALDH1A1
SCHEMBL6223628 0.79 TAAR1 (0.43) ESR1ESR2MAPK1KMT2A
SCHEMBL5109247 0.79 ESR1 (0.44) ESR1ESR2POLBRAB9ANPC1
SCHEMBL29989028 0.79 ESR1 (0.44) ESR1ESR2POLBRAB9ANPC1
SCHEMBL27933764 0.79 ESR1 (0.37) ESR1ESR2POLBRAB9ANPC1
SCHEMBL6704226 0.78 CA2 (0.41) ESR1ESR2CACNA1I

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11078194-B2 Salt form and crystal form serving as FGFR and VEGFR inhibitor compounds, and preparation method therefor Harbin Zhenbao Pharmaceutical Co., Ltd. (CN) 2021-08-03 US disclosed
EP-3333157-B1 VINYL COMPOUNDS AS FGFR AND VEGFR INHIBITORS HARBIN ZHENBAO PHARMACEUTICAL CO LTD (CN) 2020-12-23 EP disclosed
US-20200361913-A1 SALT FORM AND CRYSTAL FORM SERVING AS FGFR AND VEGFR INHIBITOR COMPOUNDS, AND PREPARATION METHOD THEREFOR Harbin Zhenbao Pharmaceutical Co., Ltd. (CN) 2020-11-19 US disclosed
EP-3722282-A1 SALT FORM AND CRYSTAL FORM SERVING AS FGFR AND VEGFR INHIBITOR COMPOUNDS, AND PREPARATION METHOD THEREFOR Harbin Zhenbao Pharmaceutical Co., Ltd. (CN) 2020-10-14 EP disclosed
US-10519133-B2 Vinyl compounds as FGFR and VEGFR inhibitors MEDSHINE DISCOVERY INC. (CN) 2019-12-31 US disclosed
US-20180222886-A1 VINYL COMPOUNDS AS FGFR AND VEGFR INHIBITORS Harbin Zhenbao Pharmaceutical Co., Ltd. (CN) 2018-08-09 US disclosed
US-20180222886-A1 VINYL COMPOUNDS AS FGFR AND VEGFR INHIBITORS Harbin Zhenbao Pharmaceutical Co., Ltd. (CN) 2018-08-09 US disclosed
EP-3333157-A1 VINYL COMPOUNDS AS FGFR AND VEGFR INHIBITORS Harbin Zhenbao Pharmaceutical Co., Ltd. (CN) 2018-06-13 EP disclosed
US-7547700-B2 Aryl-[4-halo-4(heteroarylmethylamino)-methyl]-piperidin-1-1yl]-methanone derivatives, methods for production and use thereof as medicaments PIERRE FABRE MEDICAMENT (FR) 2009-06-16 US disclosed
EP-1539738-B1 NOVEL ARYL- 4-HALO-4- HETEROARYLMETHYLAMINO)-METHYL -PIPERIDIN-1-YL -METHANONE DERIVATIVES, METHODS FOR PRODUCTION AND USE THEREOF AS MEDICAMENTS PF MEDICAMENT (FR) 2009-03-04 EP disclosed
CN-1678591-A Novel carboxamide compounds having MCH-antagonistic action, pharmaceutical preparations comprising said compounds and process for their preparation BOEHRINGER INGELHEIM INT (DE) 2005-10-05 CN disclosed
EP-1539738-A1 NOVEL ARYL- 4-HALO-4- HETEROARYLMETHYLAMINO)-METHYL]-PIPERIDIN-1-YL -METHANONE DERIVATIVES, METHODS FOR PRODUCTION AND USE THEREOF AS MEDICAMENTS PIERRE FABRE MEDICAMENT (FR) 2005-06-15 EP disclosed
EP-1534689-A1 NOVEL CARBOXAMIDE COMPOUNDS HAVING AN MCH-ANTAGONISTIC EFFECT, MEDICAMENTS CONTAINING SAID COMPOUNDS, AND METHODS FOR THE PRODUCTION THEREOF BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2005-06-01 EP disclosed
US-20040242572-A1 New carboxamide compounds having melanin concentrating hormone antagonistic activity, pharmaceutical preparations comprising these compounds and process for their manufacture BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2004-12-02 US disclosed
WO-2004024702-A1 NOVEL CARBOXAMIDE COMPOUNDS HAVING AN MCH-ANTAGONISTIC EFFECT, MEDICAMENTS CONTAINING SAID COMPOUNDS, AND METHODS FOR THE PRODUCTION THEREOF BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2004-03-25 WO disclosed
WO-2003106449-A1 NOVEL ARYL-{4-HALO-4-[HETEROARYLMETHYLAMINO)-METHYL]-PIPERIDIN-1-YL}-METHANONE DERIVATIVES, METHODS FOR PRODUCTION AND USE THEREOF AS MEDICAMENTS PIERRE FABRE MEDICAMENT (FR) 2003-12-24 WO disclosed
US-5011918-A Siloxane Derivatives Are Useful In Glass Fiber Sizing Compositions NATIONAL STARCH AND CHEMICAL INVESTMENT HOLDING CORPORATION (US) 1991-04-30 US disclosed
US-4929670-A GLASS SIZING COMPOSITIONS NATIONAL STARCH AND CHEMICAL INVESTMENT HOLDING CORPORATION (US) 1990-05-29 US disclosed
US-4839449-A SIZING COMPOSITION FOR GLASS NATIONAL STARCH AND CHEMICAL CORPORATION (US) 1989-06-13 US disclosed
EP-0314063-A2 Polysaccharides containing aromatic aldehydes and their derivatization via amine-aldehyde interactions National Starch and Chemical Corporation (US) 1989-05-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040242572-A1 New carboxamide compounds having melanin concentrating hormone antagonistic activity, pharmaceutical preparations comprising these compounds and process for their manufacture MCHR2, MCHR1, NPY1R ESR1 2176/4885ESR2 796/4885POLB 4438/4885
US-11078194-B2 Salt form and crystal form serving as FGFR and VEGFR inhibitor compounds, and preparation method therefor FGFR1, FLT1, FGFR4 ESR1 2833/4885ESR2 3752/4885POLB 4462/4885
US-10519133-B2 Vinyl compounds as FGFR and VEGFR inhibitors FGFR1, FLT1, KDR ESR1 324/4885ESR2 351/4885POLB 3498/4885
US-20200361913-A1 SALT FORM AND CRYSTAL FORM SERVING AS FGFR AND VEGFR INHIBITOR COMPOUNDS, AND PREPARATION METHOD THEREFOR FGFR1, FLT1, FGFR4 ESR1 2833/4885ESR2 3752/4885POLB 4462/4885
US-20180222886-A1 VINYL COMPOUNDS AS FGFR AND VEGFR INHIBITORS FGFR1, FLT1, KDR ESR1 324/4885ESR2 351/4885POLB 3498/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.